Wang, 236 patient remdesivir late treatment RCT: 9% higher mortality [p=1] https://c19p.org/wangr
copied to clipboard
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
et al., Lancet, doi:10.1016/S0140-6736(20)31022-9
Small RCT with 237 hospitalized patients in China with severe COVID-19, not showing statistically significant benefits. 158 treatment patients and 79 control patients.While too small for significance, the subgroup treated within 10 days showed reduced mortality RR 0.76, p = 0.58, and reduced median time to clinical improvement of 18 days vs. 23 days, hazard ratio 1.52 [0.95-2.43].[Gérard, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
|
all patients, 8.6% higher, RR 1.09, p = 1.00, treatment 22 of 158 (13.9%), control 10 of 78 (12.8%).
|
|
<10 days from symptoms, 24.3% lower, RR 0.76, p = 0.58, treatment 8 of 71 (11.3%), control 7 of 47 (14.9%), NNT 28.
|
|
>10 days from symptoms, 47.6% higher, RR 1.48, p = 0.76, treatment 12 of 84 (14.3%), control 3 of 31 (9.7%).
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Wang et al., 4/29/2020, Randomized Controlled Trial, China, Asia, peer-reviewed, 46 authors, average treatment delay 11.0 days.
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.